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LETTERS TO
THE EDITOR
Individualised pulse oximetry limits in
neonatal intensive care
EDITOR,—Gupta et al1 have successfully dem-
onstrated that they were unable to accurately
predict PaO2 from saturation monitoring
even after standardising from a previous
measurement. The rest of the conclusions
presented in their discussion are however
based upon interpretation of other research
findings which is not further supported by
their own study.
They correctly point out that the poor rela-
tion between SpO2 and PaO2 is related to dif-
fering proportions of fetal haemoglobin,
PCO2, and acid–base balance. This begs a
question, which their discussion fails to
address, on whether the PaO2 or the SpO2 is
the most useful index of oxygenation. It is
certainly the case that normal in utero PO2 is
within a range which they would describe as
“hypoxic”. On the other hand, in the
presence of 100% fetal haemoglobin, a satu-
ration monitor should, in these circum-
stances, correctly indicate adequate satura-
tion.
The authors also remark that transcutane-
ous oxygen monitoring is “a better way of
non-invasively assessing PaO2”. They provide
no evidence for this remark. It is certainly a
common experience to find a saturation
monitor alarming high when a transcutane-
ous monitor is apparently recording a normal
or even low PO2 because of an undetected
poor contact. It is also not the case that tran-
scutaneous oxygen monitoring, particularly
on the extremely premature infant, is entirely
“non-invasive”.
In the long run, the purpose of oxygen
monitoring is to detect degrees of hypoxia
which are likely to cause acidosis or tissue
damage and levels of hyperoxia which may
risk retinopathy of prematurity. To date there
would appear to be no study comparing
diVerent measurement methods with respect
to these outcomes. However, the authors’
own discussion of the reasons for the poor
correlation between SpO2 and PaO2 provides
an excellent theoretical argument in favour of
the former over the latter!
ROLLO CLIFFORD
Consultant Paediatrician,
Dorset County Hospital,Williams Avenue,
Dorchester, Dorset DT1 2JY,UK
1 Gupta R, Yoxall CW, Subedhar N, Shaw NJ.
Individualised pulse oximetry limits in neona-
tal intensive care. Arch Dis Child Fetal Neonatal
Ed 1999;81:F194-6.
Dr Yoxall and Dr Shaw respond:
Dr CliVord has raised the important question
of whether PaO2 or SpO2 is the best index of
arterial oxygenation. The answer to this
question is, of course, unknown and the aim
of our study was not to attempt to provide an
answer. Most of the work defining hypoxia
and harmful hyperoxia in neonates was
performed in the era prior to pulse oximetry
and therefore defines these situations in
terms of partial pressure rather than oxyhae-
moglobin saturation. The guidelines for good
practice in the management of neonatal
respiratory distress syndrome published by
BAPM and RCP state that arterial blood
sampling is the “gold standard” for assessing
arterial oxygenation.1 In the absence of
evidence to the contrary, we would agree with
this.
Pulse oximetry is very widely used during
neonatal intensive care. Our study has shown
that it is not possible to accurately predict
PaO2 from SpO2 even after standardising
from a previous measurement. The infor-
mation provided by measurements of PaO2
and SpO2 is diVerent and should not be
interpreted as interchangeable. As SpO2
monitoring is non-invasive, semicontinuous,
and has a rapid response time, it useful for
monitoring trends and particularly in detect-
ing episodes of sudden deoxygenation.
Monitoring of PaO2 is possible using trans-
cutaneous monitoring and this is a better way
of continuously monitoring PaO2 than trying
to extrapolate from the SpO2 signal. The ease
with which pulse oximetry can be applied has
led to the virtual abandonment of transcuta-
neous monitoring by many units. There are
technical diYculties with transcutaneous
monitoring as pointed out by Dr CliVord, but
these can be overcome if the staV caring for
the babies are familiar with the technique and
use it on a routine basis. The anecdotal expe-
riences of those units that continue to use
transcutaneous monitoring as part of their
clinical routine is that it remains an extremely
useful technique.
The purpose of maintaining adequate arte-
rial oxygenation is to provide oxygen to meet
the metabolic demands of the baby, prevent
pulmonary hypertension, and avoid oxygen
toxicity. We do not have a satisfactory method
of defining what constitutes adequate oxy-
genation during intensive care at present and
it is necessary to take into account other vari-
ables, such as haemoglobin concentration or
tissue perfusion, which also determine oxy-
gen delivery when we assess our patients.
1 Anonymous. Development of audit measures and
guidelines for good practise in the management of
neonatal respiratory distress syndrome. Report of a
joint working party of the British Association
for Perinatal Medicine and the Research Unit
of the Royal College of Physicians. Arch Dis
Child 1992;67:1221–7.
Apnoea following immunisation in
premature infants
EDITOR,—Slack and Schapira1 are correct in
drawing attention to a problem that is recog-
nised and documented but not fully ad-
dressed or understood. Their suggestion that
further studies are required to determine the
optimum timing of immunisation for ex-
tremely preterm infants is sound (even
though the adequate immunological response
of these babies to vaccinations is well
documented).
However they state that the presumed
cause of the apnoeas is the pertussis compo-
nent, with neither reference nor explanation
of why they think this is the case. As the four
antigens are given simultaneously it is not
possible to identify the culprit. The American
studies quoted2 3 could not identify whether
one or a combination of antigens was the
cause or indeed whether one of the several
other substances contained within vaccines
contributed to the reaction. Indeed Sanchez
et al merely postulate that pertussis is the
most likely reason because it has been
reported in the past to provoke more local
and systemic reactions, although the inci-
dence of associated reactions in their cohort
was low.2 Botham et al claim that pertussis
endotoxin acting centrally may stimulate
apnoeas3 although there is no evidence for
this. To determine this matter a randomised
controlled trial of whole cell pertussis, acellu-
lar pertussis, and placebo would be required.
Plainly this is not an ethical or practical
option, hence it would seem sensible to follow
the suggested advice of monitoring these
infants for 48 hours, especially in very low
birth weight infants and those with chronic
lung disease. The eVects of implementing
acellular pertussis vaccine will be awaited
with interest.
In view of recent and not so recent media
hysteria of unconfirmed (and indeed
discounted4) claims of the adverse eVects of
vaccines, we should not be fuelling this mat-
ter by making suppositions which cannot yet
be supported by the scientific evidence.
D J STALKER
Specialist Registrar,
Bristol Royal Hospital for Sick Children,
St Michael’s Hill, Bristol BS2 8BJ,UK
1 Slack MH, Schapira D. Severe apnoeas follow-
ing immunisation in premature infants. Arch
Dis Child 1999;81:F67–8.
2 Sanchez PJ, Laptook AR, Fisher L, et al.Apnea
after immunisation of preterm infants. J
Pediatr 1997;130:746–51.
3 Botham SJ, Isaacs D, Henderson-Smart DJ.
Incidence of apnoea and bradycardia in
preterm infants following DTPw and Hib
immunisation: a prospective study. J Paediatr
Child Health 1997;33:418–21.
4 Anonymous. The safety of MMR vaccine.
Current Problems in Pharmacovigilance
1999;25:9–10.
Dr Slack and Dr Schapira respond:
We thank Dr Stalker for his comments about
our report. He is quite correct that neither we
nor any of those authors who have previously
described these events have provided any evi-
dence that it is either the pertussis compo-
nent of the diphtheria/tetanus/whole cell per-
tussis vaccine or its endotoxin content that is
responsible for these reactions. That is why
we described it as “the presumed cause”.
It is possible that any of the vaccine
components or adjuvants are responsible. It
may simply be a response to pain, although
this seems unlikely. However, given the
evidence of reduced local and systemic reac-
tions with acellular pertussis vaccines in term
infants compared with the UK whole cell
vaccine,1 it seems plausible that the pertussis
component may be involved.
He is partially correct in stating that the
way to answer this would be to conduct a
three way randomised trial between placebo,
acellular (DTaP), and whole cell pertussis
(DTwP) vaccines. In fact, it would require
multiple randomisations between Hib, DT,
DTwP, one, two, three, and five component
DTaP vaccines, and placebo. Even if the use
of a placebo were ethically acceptable, which
we agree would not be the case, the low inci-
dence of these events would make the
number of infants required for such a study
impossibly large.
We are, however, conducting a multicentre
study to determine the incidence of apnoeas
following immunisation using a three compo-
nent acellular vaccine.
Finally, we do not accept that we have
joined the ranks of those who have shaken
confidence in the vaccination programme.
Arch Dis Child Fetal Neonatal Ed 2000;83:F74–F78F74
The question is not whether preterm infants
should be immunised against pertussis but
when and with what vaccine.
1 Olin P, Rasmussen F, Gustafsson L, Hallander
HO, Heijbel H. Randomised controlled trial of
two-component, three-component, and five-
component acellular pertussis vaccines com-
pared with whole-cell pertussis vaccine. Lancet
1997;350:1569–77.
Randomised controlled trial of
cisapride in preterm infants
EDITOR,—I read with great interest the study
by McClure et al1 reporting delayed gastric
emptying and a non-significant increase in
whole gut transit time in premature infants
treated with cisapride.1 In contrast, placebo
controlled studies evaluating cisapride in pae-
diatrics have almost consistently reported
improvement in symptoms of gastro-
oesophageal reflux diseases or improvement in
oesophageal pH results and/or manometry.2 As
acknowledged by the authors, other studies in
premature infants have reported a reduction in
gastric residue and improved feed tolerance. In
addition, we have reported a reduction in
gastro-oesophageal reflux in premature
infants.3
In this latest trial the authors chose
hydroxypropylmethyl cellulose as a placebo,
given at the “same volume” as cisapride;
however, the actual quantity administered is
not clear. Cellulose derivatives are commonly
employed as laxatives, where it is proposed
that they act by absorbing water, so softening
the faeces and increasing stool volume. This
in turn stimulates faecal propulsion.4 Clearly,
depending on the dose of hydroxypropyl-
methyl cellulose used, the choice of this com-
pound as a placebo is nonsensical as there
could be a marked impact on gastrointestinal
transit time. From the publication it is also
not clear why gastrointestinal motility was
measured after three days dosing; it is likely
that any cathartic eVect from a laxative would
be less marked after more prolonged treat-
ment time.
The manufacturer had recommended
against the use of cisapride in premature
infants because of concern that the metabolic
pathway of cisapride may not be fully
developed. However, in most European
countries and the United States, cisapride is
commonly used in premature (gestational age
> 34 weeks) infants, and, despite this wide-
spread use, the incidence of clinically impor-
tant cardiovascular eVects is very low. Such
events are often associated with high doses
(> 0.8 mg/kg/day) or concomitant adminis-
tration of drugs known to inhibit cytochrome
P450 that, like cisapride, are known to
prolong the QT interval.2
In my opinion, in view of the clinical
experience with cisapride in severe gastro-
oesophageal reflux disease and feed intoler-
ance in premature infants, and the few clini-
cally relevant cardiovascular events,
treatment with cisapride with appropriate
monitoring (electrocardiogram before and
after two or three days of treatment) should
not be withheld from these infants if clinically
indicated.
YVAN VANDENPLAS
Academic Children’s Hospital
Free University of Brussels
Laarbeeklaan 101
1090 Brussels, Belgium
1 McClure RJ, Kristensen JH, Grauaug A.
Randomsied controlled trial of cisapride in
preterm infants. Arch Dis Child Fetal Neonatal
Ed 1990;80:F174–7.
2 Vandenplas Y. Clincial use of cisapride and its
risk-benefit in paediatric patients. Eur J
Gastroenterol Hepatol 1998;10:871–81.
3 Vandenplas Y, Sacre L, Loeb H. The eVect of
cisapride on gastric stasis and gastro-
oesophageal reflux in premature infants. In:
Johnson AG, Lux G, eds. Progress in the
treatment of gastrointestinal motility disorders: the
role of cisapride. Amsterdam; Excerpta Medica,
1989:158–63.
4 Binder HJ. Pharmacology of laxatives? Annu
Rev Pharmacol Toxicol 1977;17:355–67.
Dr McClure responds:
We agree, and indeed stated in our own
paper1 that cisapride has been shown in chil-
dren to improve symptoms of gastro-
oesophageal reflux disease and to hasten both
gastric emptying and gastrointestinal transit
time. We believe that it is dangerous to
assume that the immature gas of the preterm
infant will react in the same manner. We fur-
ther believe that our study has the strongest
methodology of any published that has
directly examined the eVect of cisapride on
gastrointestinal motility in the preterm in-
fant. As stated in our discussion, we did not
measure gastro-oesophageal reflux and so
cannot comment on the eYcacy of cisapride
for this condition. However, in view of our
findings, until there is published evidence in a
peer reviewed journal of cisapride’s eYcacy
for this condition, we hold to our concluding
statement that it should be contraindicated as
recommended by the Medicines Control
Agencies.2
We do not believe that the choice of
hydroxypropylmethyl cellulose as a placebo
inadvertently aVected our study. The formu-
lation of cisapride suspension used in our
study contained hydroxypropylmethyl cellu-
lose. This was why this agent was chosen as
placebo. The strength of cisapride was 1
mg/ml, and therefore infants typically re-
ceived 0.2–0.3 ml per dose when receiving
placebo. Cellulose derivatives act as laxatives
by increasing faecal bulk. We do not believe
that an aqueous solution of this volume to be
anywhere near suYcient to cause this eVect.
Lastly, the significant finding of our study was
delayed gastric emptying time during cis-
apride treatment, not whole gastrointestinal
transit time.
The pharmacokinetics of cisapride in the
preterm infant are unclear. A period of three
days dosing before measurement of gastro-
intestinal motility was considered necessary
to allow both time for acquisition of a steady
serum cisapride level and adequate elimina-
tion of any previous cisapride treatment.
1 McClure RJ, Kristensen JH, Grauaug A.
Randomsied controlled trial of cisapride in
preterm infants. Arch Dis Child Fetal Neonatal
Ed 1990;80:F174–7.
2 Committee on the Safety of Medicines/
Medicines Control Agency. Cisapride (Pre-
pulsid): risk of arrhythmias. Current Problems
in Pharmacovigilance 1998;24:11.
The use of cisapride in neonates
EDITOR,—In response to the annotation of
Markiewicz and Vandenplas,1 in which they
give the indications for the use of cisapride in
neonates, I performed a Medline search using
the search terms “cisapride” and “infant,
newborn”. This disclosed only three ran-
domised controlled trials of cisapride versus
placebo in neonates.2–4 One other study com-
pared cisapride with placebo in infants, but
only a subgroup of this study population were
neonates (number not stated).5 None of these
studies were referenced in their annotation.1
Surely in these days of evidenced based
medicine, direct examination of the evidence
available is mandatory.
The results of the trials found in my search
show that cisapride is only eVective in: treat-
ing ileus after abdominal surgery4; reducing
the number of gastric residuals in nasogastri-
cally fed preterm infants3; and decreasing the
incidence of regurgitation in preterm infants.3
Specifically cisapride was not eVective in
reducing the time taken to achieve full enteral
feeds in preterm infants,3 and may delay gas-
tric emptying in preterm infants.2
Furthermore it could be argued that
gastro-oesophageal reflux is a non-
pathological state in neonates, and only if it
leads to complications (secondary respiratory
disease, oesophagitis) does it require treat-
ment. No randomised controlled trial of
cisapride versus placebo in neonates has been
published that looks at these clinically
relevant outcomes.
I would therefore argue that, given the side
eVect profile, the only indications for cis-
apride in neonates are treatment of postop-
erative ileus and, possibly, treatment of
regurgitation leading to complications. At
present there is no evidence that it is eVective
for use in neonates in any other circumstance.
MARK W DAVIES
Perinatal Research Centre
University of Queensland
Royal Women’s Hospital
Brisbane, Australia 4029
1 Markiewicz M, Vandenplas Y. Should cisapride
have been “blacklisted”? Arch Dis Child Fetal
Neonatal Ed 2000;82:F3–4.
2 McClure RJ, Kristensen JH, Grauaug A.
Randomised controlled trial of cisapride in
preterm infants. Arch Dis Child Fetal Neonatal
Ed 1999;80:F174–7.
3 Enriquez A, Bolisetty S, Patole S, Garvey PA,
Campbell PJ. Randomised controlled trial of
cisapride in feed intolerance in preterm
infants. Arch Dis Child Fetal Neonatal Ed
1998;79:F110–13.
4 Lander A, Redkar R, Nicholls G, et al. Cisapride
reduces neonatal postoperative ileus: ran-
domised placebo controlled trial. Arch Dis
Child Fetal Neonatal Ed 1997;77:F119–22.
5 Vaneygen M, Vanravensteyn H. EVect of
cisapride on excessive regurgitation in infants.
Clin Ther 1989;11:669–77.
Mechanism of blood pressure increase
induced by dopamine in hypotensive
preterm neonates
EDITOR,—The paper of Zhang et al1 on the
eVects of dopamine relies on the assumption
that left ventricular output (LVO) is a
measure of systemic blood flow (SBF). This
is not true in the presence of any shunt
through the ductus arteriosus where LVO
becomes the sum of SBF and volume of
blood shunting back into the lungs through
the duct, and so overestimates SBF. While
Zhang et al1 define the ducts in their study
babies as insignificant, we would question the
validity of the criteria used to make this defi-
nition. We have never seen shunting only in
diastole, chamber enlargement is an incon-
sistent sign of ductal significance which
develops after day one,2 and shunt velocity
has little relation to shunt size during week
one.3 In fact, the left to right velocity often
increases as the duct constricts and the shunt
diminishes in size.3 Bidirectional shunting is
also usually predominantly left to right.
There is much in the data presented by
Zhang et al1 to suggest that these ducts were
highly significant. Firstly, they selected a
population at high risk for a significant duct,4
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and secondly they measured a mean diameter
of 2.9 mm. We showed that this measure is
the most accurate predictor of early haemo-
dynamic significance and that preterm ducts
over 2 mm in diameter, with very few excep-
tions, have a haemodynamic impact.3 5 In this
haemodynamic milieu, LVO is actually a
measure of pulmonary blood flow, and right
ventricular output becomes the better meas-
ure of SBF,5 but even this can be confounded
by the common finding of left to right atrial
shunting.3 6 That this haemodynamic impact
is often present from the very early postnatal
period is emphasised in fig 1 which is of a 5
hour old infant of 26 weeks gestation, in
whom we measured an LVO of 350 ml/min
per kg but a right ventricular output (RVO) of
90 ml/min per kg. This baby had an
unrestricted duct (2.6 mm) with a low veloc-
ity (0.7 m/s) but high volume left to right
shunt. In other words LVO was overestimat-
ing SBF by a factor of over 300%. This is not
an unusual finding.3
This means that the changes in LVO in
response to dopamine documented by Zhang
et al1 may have occurred in the systemic
circulation but, equally, could have occurred
in the pulmonary circulation. The same
uncertainty applies to changes in calculated
vascular resistance. In other words, LVO may
have increased or decreased solely because
dopamine has changed the volume of the
ductal shunt back into the lungs.
Early preterm ductal shunting should not
be assumed to be inconsequential, and
interpretation of early postnatal measures of
either right or left ventricular output in
preterm infants should be approached with
caution.
NICK EVANS
DAVID OSBORN
MARTIN KLUCKOW
Department of Neonatal Medicine
King George V Hospital for Mothers and Babies
Royal Prince Alfred Hospitals
Missenden Road
Camperdown
NSW 2050, Australia
email: nevans@med.usyd.edu.au
1 Zhang J, Penny DJ, Kim NS, Yu VYH, Smolich
JJ. Mechanism of blood pressure increase
induced by dopamine in hypotensive preterm
neonates. Arch Dis Child Fetal Neonatal Ed
1999;81:F99–104.
2 Iyer P, Evans NJ. Re-evaluation of the left atrial
to aortic root ratio as a marker of patent duc-
tus arteriosus.Arch Dis Child Fetal Neonatal Ed
1994;70:F112–17.
3 Evans NJ, Iyer P. Assessment of ductus arterio-
sus shunting in preterm infants requiring ven-
tilation: eVect of inter-atrial shunting. J Pediatr
1994;125:778–85.
4 Evans NJ, Moorcraft J. EVect of patency of the
ductus arteriosus on blood pressure in very
preterm infants.Arch Dis Child 1992;67:1169–
73.
5 Evans NJ, Kluckow M. Early determinants of
right and left ventricular outputs in ventilated
preterm infants. Arch Dis Child Fetal Neonatal
Ed 1996;74:F88–94.
6 Evans NJ, Iyer P. Incompetence of the foramen
ovale in preterm infants requiring ventilation.
J Pediatr 1994;125:786–92.
Dr Zhang et al respond:
Dr Evans and his colleagues have raised two
main issues about our paper.1 The first relates
to the haemodynamic significance of shunt-
ing through the ductus in our subjects. We
readily acknowledge that shunting was
present and that the measured left ventricular
output was therefore an approximation of
systemic tissue blood flow. This was unavoid-
able, as most babies were studied on the first
day after birth, when the ductus is proceeding
to close.2 However, on the basis of clinical
assessment as well as other data not
presented—for example, average left ven-
tricular shortening fraction was 29%—we
considered that myocardial dysfunction
rather than ductal shunting was the most
likely cause of the systemic hypotension
shown.
Our study was confined to a select
subgroup of babies with hypotension who
failed to respond to volume loading and were
thus started on inotropes. In contrast, the
studies cited by Evans and colleagues were
performed in groups of infants who may or
may not have received volume loading and/or
inotropic treatment3–7 and in whom the level
of myocardial function ranged from de-
pressed to normal.6 Furthermore, most of our
subjects were studied within the initial 24
hours after birth, whereas the studies cited3–7
were performed over the course of the first
postnatal week. Given the substantial physi-
ological changes in the cardiovascular
system,8 9 findings obtained in the middle or
end of the initial week may not necessarily be
applicable to the first day after birth.
Evans and colleagues state that “left
ventricular output may have increased or
decreased solely because dopamine changed
the volume of the ductal shunt back to the
lungs”. The physiological changes we ob-
served suggest that this was unlikely and that
dopamine exerted a vasoactive eVect within
the systemic circulation. Thus the premise
that the increase in left ventricular output was
related only to greater left to right ductal
shunting is not in accord with the concomi-
tant rise in systemic blood pressure induced
by dopamine. The contention that falls in left
ventricular output were merely due to a
reduction in ductal shunting is inconsistent
with the observed fall in superior mesenteric
artery velocity and rise in superior mesenteric
vascular resistance.
A possibility deserving of consideration is
that dopamine changed the degree of ductal
shunting and that this comprised one compo-
nent of the alteration in left ventricular
output. We are not aware of any published
data in newborn infants that support direct
relaxation or constriction of the ductus by
dopamine or of a diVerential eVect of
dopamine on the systemic and pulmonary
vascular beds. Indeed, in studies performed
in newborn lambs, we observed that, at infu-
sion rates of up to 15 µg/min per kg, the sys-
temic and pulmonary vascular eVects of
dopamine were proportionally similar in
magnitude (J J Smolich, H Park, and D J
Penny, unpublished observations). In our
view therefore it was reasonable to assume
that, while ductal shunting was present in our
babies, the degree was not altered to a
substantial extent by dopamine. However, the
notion that inotropic treatment could alter
ductal shunting in preterm infants has poten-
tially important clinical ramifications and so
is worth investigating.
Finally, although we agree that the illustra-
tive example of the degree of dissociation
which may occur between the level of left and
right ventricular outputs is striking, examina-
tion of group data from the same laboratory
suggests that, on average, left ventricular out-
put is only 7–15% higher than right ventricu-
lar output in ventilated preterm infants.6
Moreover, while we did not include the data
in our paper, the pulmonary trunk velocity-
time integral in our infants was not signifi-
cantly diVerent from the ascending aortic
velocity-time integral (p > 0.9), suggesting
that the marked degree of dissociation
between ventricular outputs evident in the
illustrative example was not a feature of the
babies in our study.
J J SMOLICH
J ZHANG
D J PENNY
V Y H YU
Centre for Heart and Chest Research
Department of Medicine
Monash University
Department of Paediatrics
Monash University
1 Zhang J, Penny DJ, Kim NS, Yu VYH, Smolich
JJ. Mechanism of blood pressure increase
induced by dopamine in hypotensive preterm
neonates. Arch Dis Child Fetal and Neonatal Ed
1999;81:F99–104.
2 Yu VYH. Patent ductus arteriosus in the
preterm infant. Early Hum Dev 1993;35:1–14.
3 Iyer P, Evans NJ. Re-evaluation of the left atrial
to aortic root ratio as a marker of patent duc-
tus arteriosus. Arch Dis Child Fetal and Neona-
tal Ed 1994;70:F112–17.
4 Evans NJ, Iyer P. Assessment of ductus arterio-
sus shunting in preterm infants requiring ven-
tilation: eVect of inter-atrial shunting. J Pediatr
1994;125:778–85.
5 Evans NJ, Moorcraft J. EVect of patency of the
ductus arteriosus on blood pressure in very
preterm infants.Arch Dis Child 1992;67:1169–
73.
6 Evans NJ, Kluckow M. Early determinants of
right and left ventricular outputs in ventilated
preterm infants. Arch Dis Child Fetal and Neo-
natal Ed 1996;74:F88–94.
7 Evans NJ, Iyer P. Incompetence of the foramen
ovale in preterm infants requiring ventilation.
J Pediatr 1994;125:786–92.
8 Walker AM. Circulatory transitions at birth and
the control of the neonatal circulation. In: MA
Hanson, JAD Spencer, CH Rodeck, eds. Fetus
and neonate: physiology and clinical applications.
Volume 1: the circulation. Cambridge: Cam-
bridge University Press, 1993:160–96.
9 Smolich JJ, Berger PJ, Walker AM. Interrelation
between ventricular function, myocardial
blood flow and O2 consumption changes at
birth in lambs. Am J Physiol 1996;270:
H741–9.
Figure 1 Doppler measures taken from a 26 week infant at 5 hours of age. (A) High velocity flow
(about 1.0 m/s) in the ascending aorta representing a left ventricular output of 350 ml/min per kg.
(B) Low velocity flow (about 0.2 m/s) in the pulmonary artery representing a right ventricular
output of 90 ml/min per kg. (C) Low velocity (about 0.7 m/s) high volume laminar left to right flow
through an unconstricted duct.
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Retained umbilical artery catheter
presenting as an umbilical abscess
EDITOR,—We report the delayed recognition
of an umbilical artery catheter in an 18
month infant who presented with recurrent
umbilical discharge.
A male infant was delivered by caesarian
section which was complicated by a hypogly-
caemic fit. Resuscitation included the at-
tempted insertion of an umbilical venous
catheter. The line was found to be arterial
and thus removed. A second attempt also
entered the umbilical artery, and, as the
infant was now stable, no further attempt was
made.
At 15 months, the infant presented with an
umbilical abscess. This was investigated after
drainage to exclude a urachal remnant. An
ultrasound and abdominal radiograph
showed a foreign body within the common
iliac artery, and, using an infraumbilical
approach, part of an umbilical catheter was
removed. The remnant was 10 cm in length.
During the neonatal period, the umbilicus
is a useful route of vascular access. The
umbilical artery can be used for blood
pressure and gas tension measurement but all
catheters should be removed early to avoid
central infection.1 Other complications such
as thrombosis and necrotising enterocolitis
have been reported.2 Migration of umbilical
vein catheters into the left atrium and pulmo-
nary veins may occur.3 Retrieval of fractured
umbilical catheters during the neonatal pe-
riod has been reported.4
In this case, the retained catheter was not
recognised until the infant presented late with
recurrent umbilical infections and illustrates
a new addition to our list of diVerential diag-
noses. The history also re-emphasises that it
is essential to check central lines for com-
pleteness on removal.
R KOTNIS
A SALLOUM
R HITCHCOCK
Department of Paediatric Surgery, John RadcliVe
Hospital, Oxford
1 Rossi P. Hook catheter technique for transfemo-
ral removal of foreign body from right side of
the heart. Am J Roentgenol 1990;108:101–6.
2 Wagner CW, Vinocur CD, Weintraub WH.
Retrieval of an umbilical artery catheter: a
potential for misadventure. South Med J
1987;80:1434–5.
3 Ruiz CE, Nystrom GA, Butt AI, Zhang HP. Per-
cutaneous retrieval of a broken umbilical cath-
eter from left atrium in a premature newborn.
Cathet Cardiovasc Diagn 1995;36:265–8.
4 Simon-Fayard EE, Kroncke RS, Solarte D,
Peverini R. Nonsurgical retrieval of embolised
umbilical catheters in premature infants. J
Perinatol 1997;17:143–7.
Premedication for neonatal intubation:
current practice in Australia and the
United Kingdom
EDITOR,—The paper by Bhutada et al1 adds to
the growing body of evidence that premedica-
tion for tracheal intubation in neonates both
improves physiological stability and makes
the procedure easier to perform. The results
of the telephone survey of premedication use
in UK neonatal units by Whyte et al2 helps to
define current practice. In a similar study, we
recently tried to define the routine use of pre-
medication for tracheal intubation in term
and preterm neonates in Australia and the
United Kingdom, allowing comparisons to be
made.
A survey was conducted of practice in Aus-
tralian level 3 units (21) and UK units with
six or more intensive care cots (52). The for-
mat was a semistructured telephone inter-
view of the nurse in charge of the shift when
the call was made. All interviews were
conducted by one of two of the authors (S H
and J B) in September 1999. There was a
100% response rate, and the results are given
in table 1.
Seven diVerent combinations of premedi-
cation drugs were in routine use in Australia
compared with 14 diVerent combinations in
the United Kingdom.
In Australian units, the routine administra-
tion of premedication for non-emergency
tracheal intubation of term and preterm
neonates is common practice, and there is
some uniformity in the combinations of
drugs used. In contrast, this practice is less
common in the United Kingdom and there is
more diversity of prescribing. In both coun-
tries, premedication was more commonly
used for term neonates. This diVerence in
practice may reflect the fact that larger babies
are more likely to struggle when intubated,
making the procedure more technically de-
manding.
We agree with Whyte et al that there is a
strong evidence based argument for premedi-
cation for tracheal intubation in neonates to
be routine. Our work brings added clarity to
the existing picture and confirms that there is
little consensus as to the best combination of
drugs to use. Further work to define best
practice is urgently required.
STEPHEN HANCOCK
Department of Anaesthesia
Bradford Royal Infirmary
SIMON NEWELL
St James’s University Hospital
Leeds
JOE BRIERLEY
ANDREW BERRY
New South Wales Newborn and Paediatric Emergency
Transport Service
Wentworthville, NSW,Australia
1 Bhutada A, Sahani R, Rastogi S, Wung J-T.
Randomised controlled trial of thiopental for
intubation in neonates. Arch Dis Child Fetal
Neonatal Ed 2000;82:F34–7.
2 Whyte S, Birrell G, Wyllie J. Premedication
before intubation in UK neonatal units. Arch
Dis Child Fetal Neonatal Ed 2000;82:F38–41.
Perinatal cortical infarction with no
obvious cause
EDITOR,—The study by Govaert et al of ultra-
sonography in newborn infants with perinatal
cortical infarctions1 did not find a cause in
25% of cases. They also confirmed an associ-
ation between stroke and pulmonary hyper-
tension requiring assisted ventilation.2
We have previously published observations
on artificially ventilated newborn piglets with
pneumothorax and pulmonary hypertension,
showing cerebral arterial air microembolisa-
tions.3 4 In the case of artificial ventilation,
which is often accompanied by pulmonary air
leak syndrome (pulmonary interstitial em-
physema, pneumomediastinum, pneumotho-
rax), air can easily reach the cerebral vascula-
ture, especially when there is persistent
pulmonary hypertension and right to left
intracardiac shunts.
In the light of our observations, as air
microemboli could not be detected by
ultrasound, I suspect that the perinatal corti-
cal infarction may have been due to cerebral
arterial air embolisation in some patients in
the study by Govaert et al.
PÉTER TEMESVÁRI
Department of Pediatrics
University Teaching Hospital
Kecskemét, Hungary
email : temespete@hotmail.com
1 Govaert P, Matthys E, Zecic A, Roelens F, Oos-
tra A, Vanzieleghem B. Perinatal cortical
infarction within middle cerebral artery trunks.
Arch Dis Child Fetal Neonatal Ed 2000;82:F59–
63.
2 Klesh KW, Murphy TF, Scher MS, Buchanan
DE, Maxwell EP, Guthrie RD. Cerebral
infarction in persistent pulmonary hyper-
tension of the newborn. American Journal of
Diseases in Children 1987;141:852–7.
3 Temesvári P, Kovács J, Rácz K. Cerebral arterial
air embolisation in experimental neonatal
pneumothorax. Arch Dis Child 1989;64:179.
4 Temesvári P, Kovács J, Ábrahám CS. Pneumot-
horax and neonatal stroke. Neuropediatrics
1996;27:167–8.
Neonatal pain relief
EDITOR,—The study of Jain and Rutter1 indi-
cates that, after an hour of application, topical
amethocaine gel exerts a demonstrable anaes-
thetic eVect 54.8% of the time, indicating low
potential for practical use. In the authors’
own words “a successful . . . anaesthetic
should be quick acting, eVective and safe . . .”.
It is therefore disappointing to note that in
the discussion no mention was made of oral
sucrose as an analgesic agent for use in
neonates undergoing painful procedures.
This is despite a large body of evidence sug-
gesting that it reduces the indicators of pain
from various sources.2 3 Unfortunately there
is a widespread reluctance of clinicians to use
oral sucrose before performing painful proce-
dures on neonates. We showed this in a recent
study.4
Questionnaires were sent to the medical
directors of the 18 neonatal units in New
Zealand in order to determine the knowl-
edge, attitudes, and practice with regard to
commonly performed painful neonatal pro-
cedures such as blood taking or line place-
ment. In the 15 replies, there was a high
degree of awareness that the procedures
caused pain (100%), that the physiological
stress of pain was more hazardous than the
risks of analgesia (67%), and that oral sucrose
was a safe and eVective analgesic (87%); and
yet only five units (33%) ever used any type of
analgesia for these procedures and usually for
less than 10% of the time. Only one unit (our
own) used oral sucrose routinely. We find it to
Table 1 Results of survey of premedication practice for tracheal intubation in term and preterm
neonates in Australia and the United Kingdom
United Kingdom Australia
Term Preterm Term Preterm
Routine premedication (%) 22 (42) 18 (34) 15 (71) 14 (67)
Opiate 13 11 2 4
BDZ 1 0 2 1
Opiate + BDZ 1 1 0 0
Opiate + muscle relaxant ± atropine 6 6 11 9
BDZ + muscle relaxant ± atropine 1 0 0 0
BDZ, benzodiazepine.
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be highly eVective, simple to use, and rapid in
action. It is also exceedingly cheap.
We do not know why oral sucrose has failed
to find much favour in neonatal units. Clearly
neither lack of understanding of neonatal
pain perception nor lack of knowledge about
the analgesic properties of sucrose are signifi-
cant factors. Perhaps there is an unrecognised
prejudice against anything that is low tech,
cheap, and not promoted by pharmaceutical
companies.
PAUL HEATON
DAVID HERD
Child and Adolescent Community Centre
Taranaki Health
Private Bag 2016
New Plymouth 4620,New Zealand
email: paed.cacc@thcl.co.nz
1 Jain A, Rutter N. Local anaesthesia eVect of
topical amethocaine gel in neonates: ran-
domised controlled trial. Arch Dis Child Fetal
Neonatal Ed 2000;82:F42–5.
2 Stevens B, Ohlsson A. Sucrose for analgesia in
newborn infants undergoing painful proce-
dures. Cochrane Library, Issue 3. Oxford:
Update Software, 1999.
3 Ramenghi LA, Wood CM, GriYth GC, Levene
MI. Reduction of pain response in premature
infants using intraoral sucrose. Arch Dis Child
Fetal Neonatal Ed 1996;74:F126–8.
4 Heaton PAJ, Herd DW. Analgesia for simple
neonatal procedures: a survey of New Zealand
neonatal units. New Zealand Paediatric Society
Annual Scientific Meeting,Wellington 1999.
BOOK REVIEWS
Prenatal care. EVectiveness and
implementation. Edited by Marie C
McCormick and Joanna E Siegel [Pp363;
£39.95] Cambridge University Press, 1999.
ISBN 0-521-66196-X.
After fifty years, my only real memory of the
paediatrics teaching of Professor A V Neale in
Bristol is the benefit to children of sunlight
and the aphorism “Preconceptual and Prena-
tal care is crippled by a large proportion of
the disadvantaged population who further
disadvantage themselves by their own ac-
tions”. Regrettably this text from the USA
shows us that little has changed. Over these
decades the rate of prematurity, intrauterine
growth retardation (IUGR) and perinatal
mortality has changed very little in spite of all
our collective clinical eVorts.
The male partner is hardly mentioned in
this book so it seems that, to American eyes,
the sole responsibility for producing healthy
or unhealthy babies lies with the mother. All
of us now know that many varied vaginal
infections are associated with premature/pre-
labour rupture of the membranes and prema-
turity itself and that antibiotic treatment may
have a reducing eVect on these problems. Yet
with a close reading of the chapter on vaginal
infections, which is very well referenced,
there appear to be no papers indicating that
with all these infections possibly being
sexually transmitted, no trials have included
investigation and treatment of the male part-
ner. For example, although Bacterial Vagino-
sis, Candida and Haemolytic Streptococcus
are not usually recognised as sexually trans-
mitted diseases (STD), all gynaecologists
have witnessed cases where they have been
the cause of recurrent vaginal infections.
Many chapters emphasise the adverse
eVects of alcohol, smoking, recreation drugs
and poverty on the unborn fetus. I have
always had a healthily sceptical interest in
Jongbloet’s1 theory that alcohol consumption
just before and at the time of conception may
be responsible for a large number of chromo-
somal aberrations but this attractive theory is
nowhere to be found in the book.
Meanwhile we are beset by new threats. A
recent study,2 not mentioned in this book,
shows ecstasy exposure being implicated in
some congenital anomalies.
This is a well researched book with
excellent references. Throughout, areas of
research yet to be carried out are mentioned.
For that reason alone it could serve as a good
“ideas” source book for junior paediatricians
and obstetricians to involve themselves in
research projects which may one day help to
reduce the continuing high incidence of
potentially-damaged babies.
JOHN MCGARRY
Consultant Obstetrician and Gynaecologist in
Independent Practice North Devon
1 Jongbloet PH. Prepregnancy Care: Background
Biological EVects. Prepregnancy Care. A
Manual for Practice. 1986;31–52.
2 McElhatton PR, Bateman DN, Evans C, Pughe
KR, Thomas SHL. Congenital anomalies after
prenatal ecstacy exposure. The Lancet
1999;354:1441–42.
Practical Perinatal Care—The Baby
Under 1000 Grams. Gill Levitt, David
Harvey, Richard Cooke [$165.00].
Butterworth Heinemann Hardback ISBN
0-7506-1717-9.
Many will have experienced a feeling of being
daunted when beginning a neonatal post as a
doctor in training or as a neonatal nurse. The
smaller the infant with which to be faced, the
greater the concern over the ability to manage
the infant appropriately. Levitt, Harvey and
Cooke’s Practical Perinatal Care—The Baby
Under 1000 Grams goes a long way to provide
a very readable but authoritative book which
will help prepare those in neonatal medical or
nurse training to manage these infants. The
book has a wide range of chapters from the
practical aspects of how to put in an arterial
line, perform a suprapubic aspiration of the
bladder or drain a pneumothorax, to ventila-
tion strategies, and ethical issues of the man-
agement of extremely low birth weight
infants. The authors have rightly concen-
trated on the subgroup of neonatal patients
who are less than 1000g at birth as these are
undoubtedly the most challenging group,
where there is the greatest mortality and
morbidity, and where there is the possibility
to improve the outcome with good care. Each
chapter is relatively short but provides clear
information from an evidence based perspec-
tive where available and is very well refer-
enced. There is an informative chapter on
iatrogenic disease which reminds the reader
as to the damage which may result from the
procedures and treatment given, especially if
care is not taken. All chapters conclude with
a highlighted box of Practical Points and
there are useful diagrams and a series of black
and white photographs to aid the text,
although occasionally these are too small to
be of real value such as in the procedures
chapter. Any senior house oYcer, specialist
registrar, or neonatal nurse starting a neona-
tal post would be well advised to read this
useful book which will sit nicely between the
several general neonatal texts that are avail-
able and the more definitive works which will
remain the mainstay of neonatal reference.
ANTHONY J B EMMERSON
Consultant Paediatrician
St Mary’s Hospital
Manchester
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